Previous 10 | Next 10 |
2023-07-12 10:03:23 ET Gainers: Healthcare Triangle ( HCTI ) +183% . Recursion Pharmaceuticals ( RXRX ) +71% . Cadrenal Therapeutics ( CVKD ) +43% . Liminal BioSciences ( LMNL ) +40% . Eloxx Pharmaceuticals ( ELOX ) +29% . L...
2023-07-12 08:16:40 ET ShiftPixy ( PIXY ) -33% on pricing of $3.1 Million public Offering . Silk Road Medical ( SILK ) -23%. PainReform ( PRFX ) -24% . WANG & LEE GROUP ( WLGS ) -10% . NanoViricides ( NNVC ) -8% . CytoMed...
2023-07-11 13:19:00 ET Gainers: Eloxx Pharmaceuticals ( ELOX ) +112% . CytoMed Therapeutics Limited ( GDTC ) +102% . Biodexa Pharmaceuticals ( BDRX ) +92% . SOS Limited ( SOS ) +39% . Freeline Therapeutics Holdings ( FRLN ) +33% ...
(NewsDirect) By David Willey, Benzinga Read the latest report on NanoViricides here . NanoViricides (NYSE American: NNVC) has begun trials for its new drug candidate, NV-CoV-2 — an exciting development for the biotech company, as it starts its first human tr...
--News Direct-- By David Willey, Benzinga Read the latest report on NanoViricides here . NanoViricides (NYSE American: NNVC) has begun trials for its new drug candidate, NV-CoV-2 — an exciting development for the biotech company, as it starts its first human...
SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its broad-spectrum antiviral clinica...
(NewsDirect) By David Willey, Benzinga Read the latest report on NanoViricides here . NanoViricides (NYSE American: NNVC) is a drug development company working on a novel nanomedical treatment. It recently updated the world on the status of its long-awaited and now...
SHELTON, CO / ACCESSWIRE / July 6, 2023 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily. NanoViricides is a clinical-stage global leader in the development of highly effectiv...
--News Direct-- NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share news about the beginning of clinical trials for its broad-spectrum antiviral drug NV-CoV-2. This is with two oral drug products NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies. Diwan told Proac...
SHELTON, CT / ACCESSWIRE / June 29, 2023 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. "We bel...
News, Short Squeeze, Breakout and More Instantly...
NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on F...
Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE / May 14, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity o...